CareDx (CDNA) Could Be 14% Undervalued After Medicare Coverage Win And Strong Q3
CareDx (CDNA) has been in focus after Medicare expanded coverage for its transplant tests. This move coincided with strong third quarter results and an upward revision to full year revenue guidance.
CareDx’s share price has surged over the year, with a year-to-date share price return of 322% and a very large 3-year total shareholder return. However, the stock has recently cooled, with a 7-day share price decline of 8.7% after the initial Medicare-driven jump.
Scan for other transplant and healthcare specialists showing similar momentum with the curated list of 36 healthcare AI stocks.
After a 322% year to date run and a recent pullback, CareDx now trades below both its analyst target and an intrinsic value estimate. Is the stock still stretched, or has the gap opened up enough to argue for a discount?
Most Popular Narrative: 13.6% Undervalued
CareDx last closed at $80.77, while the analyst consensus Narrative on Simply Wall St places fair value at $93.50 using a 7.5% discount rate. This frames the stock as modestly undervalued against those long range cash flow assumptions.
Refocusing on high margin CLIA testing and digital services after the sale of the Lab Products business, together with non GAAP gross margins of about 74% and adjusted EBITDA margins above 20% in recent quarters, points to an operating model that may continue to support earnings and cash flow expansion.
See why 8 investors see CareDx as 14% undervalued.
Result: Fair Value of $93.50 (UNDERVALUED)
Still, the CareDx story can unravel if its premium P/E compresses, or if transplant and oncology testing fail to track the analyst growth assumptions.
Find out about the key risks to this CareDx narrative.
Another View on CareDx’s Valuation
On cash flow assumptions, CareDx screens as attractive, with the stock trading about 29.6% below an internal estimate of its future cash flow value at $114.65 per share. On earnings, the picture flips, since a P/E of 33x is rich versus the US Biotechs sector on 16x and a fair ratio of 12.3x. For investors, that split raises a simple question: which signal deserves more weight, the discounted cash flow or the premium earnings multiple that the market could move toward the fair ratio over time?
To see how this earnings based view stacks up against other ways of looking at CareDx, have a look at See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Mixed signals around CareDx can feel energising or unsettling. Act while the details are fresh and weigh both sides for yourself with the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond CareDx?
If CareDx has you thinking differently about opportunity and risk, do not stop here. Broaden your watchlist now or you may overlook your next key idea.
- Target resilient opportunities by scanning a 30 resilient stocks with low risk scores that keeps volatility scores in focus while you search for steadier potential performers.
- Hunt for quality at a discount by using the 35 high quality undervalued stocks that filters for businesses combining stronger fundamentals with pricing that may lag intrinsic estimates.
- Spot potential early movers by reviewing a 10 elite penny stocks with strong financials that highlights smaller companies with the balance sheets and financial traits to support further progress.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com